AbbVie Sues to Block Copies of Orilissa Endometriosis Drug (1)

AbbVie Inc. alleges in a federal lawsuit that copies of Orilissa proposed by nine generic-drug makers, including Novartis AG’s Sandoz Inc. and Lupin Ltd., infringe as many as six patents for the drug, used to manage pain associated with endometriosis.

Three of the patents are licensed from Neurocrine Biosciences Inc., according to a complaint filed Thursday and docketed Friday in the US District Court for the District of Delaware.

The suit also targets generic versions of Orilissa proposed by Alkem Laboratories Ltd., Hetero Labs Ltd., MSN Laboratories Private Ltd., Zhejiang Huahai Pharmaceutical Co. and its Prinston ...